US Pharma MarketingGene editor Scribe starts second-half IPO spree with $129M listing
A 9-year-old biotech co-founded by CRISPR pioneer Jennifer Doudna is kicking off a run of biotech IPOs set for this year's second half. Scribe Therapeutics priced its $128.7 million
A 9-year-old biotech co-founded by CRISPR pioneer Jennifer Doudna is kicking off a run of biotech IPOs set for this year's second half.
Scribe Therapeutics priced its $128.7 million
Source: Endpoints News